- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/73 - CD4
Patent holdings for IPC class C07K 14/73
Total number of patents in this class: 326
10-year publication summary
|
16
|
22
|
23
|
51
|
35
|
40
|
35
|
35
|
30
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4608 |
35 |
| City of Hope | 1017 |
21 |
| Mcmaster University | 825 |
16 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2971 |
12 |
| Immatics Biotechnologies GmbH | 1118 |
8 |
| Memorial Sloan-Kettering Cancer Center | 2002 |
6 |
| The Trustees of the University of Pennsylvania | 4406 |
5 |
| Juno Therapeutics, Inc. | 487 |
5 |
| University of Florida Research Foundation, Inc. | 4147 |
4 |
| ViiV Healthcare UK (no.5) Limited | 88 |
4 |
| Shattuck Labs, Inc. | 123 |
4 |
| The Board of Trustees of the Leland Stanford Junior University | 6592 |
3 |
| Board of Regents, The University of Texas System | 6045 |
3 |
| The Johns Hopkins University | 5821 |
3 |
| Autolus Limited | 266 |
3 |
| Beijing Solobio Genetechnology Company Ltd. | 35 |
3 |
| Children's National Medical Center | 278 |
3 |
| The Council of the Queensland Institute of Medical Research | 165 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2645 |
3 |
| eFFECTOR Therapeutics, Inc. | 67 |
3 |
| Other owners | 179 |